Glutaurine Compositions for Thyroid Atrophy Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current thyroidal compounds used for treating thyroid disorders and weight conditions cause thyroid gland atrophy, leading to diminished effectiveness over time, and existing therapeutic agents for estrogen-sensitive conditions often stimulate unwanted tissue growth and increase cancer risk.
Innovation Solution
Administration of glutaurine or its derivatives, such as salts, esters, and functional derivatives, which increase T3 levels while decreasing estrogen levels, thereby promoting weight loss, maintaining muscle mass, and restoring normal thyroid function without causing thyroid atrophy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If thyroidal compounds (T3, T4, diiodothyronine) are administered to treat thyroid disorders and increase metabolism, then weight loss and energy expenditure are improved, but thyroid gland atrophy occurs due to negative feedback
Solution Approach 1:
The patent introduces glutaurine as an intermediary substance that mediates between thyroid hormone administration and thyroid gland function. Glutaurine acts as a protective agent that prevents atrophy while allowing thyroidal compounds to maintain their metabolic effects, thus resolving the contradiction between improving metabolism and preventing gland damage
Solution Approach 2:
The patent changes the chemical and functional parameters of the therapeutic system by combining thyroidal compounds with glutaurine. This parameter change allows the system to achieve high metabolic activity without the harmful negative feedback that causes atrophy, as glutaurine modifies the pharmacological profile of the treatment
2Reliability
If estrogen is administered to treat estrogen-sensitive conditions, then therapeutic effects are achieved, but unwanted tissue growth and cancer risk increase
Solution Approach 1:
The patent uses glutaurine as an intermediary that modifies the action of estrogenic substances. Instead of directly administering estrogen, the composition combines glutaurine with estrogenic agents to achieve therapeutic effects while preventing the harmful stimulation of estrogen-sensitive tissues, thus resolving the contradiction between therapeutic reliability and cancer risk
Solution Approach 2:
The patent converts the potentially harmful effect of estrogenic stimulation into a beneficial outcome by using glutaurine to selectively modulate estrogen activity. The composition achieves therapeutic effects in estrogen-sensitive conditions while preventing unwanted tissue growth, effectively transforming a harmful substance into a safe and effective treatment
Data Source
AI summary
The present disclosure provides compositions and methods useful for the treatment of a body weight condition or a thyroid disorder. The compositions induces increased T3 levels while preventing thyroidal atrophy. Also provided are compositions and methods for the treatment of a disease or condition that is estrogen sensitive, estrogen receptor dependent or estrogen receptor mediated such as breast cancer.